Quantifying the value of orally delivered biologic therapies: A cost-effectiveness analysis of oral semaglutide
© 2019 American Pharmacists Association® Oral semaglutide, which has undergone multiple phase 3 clinical trials, represents the first oral biologic medication for type 2 diabetes in the form of a daily capsule. It provides similar efficacy compared with its weekly injection counterpart, but it deman...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier BV,
2022-01-28T19:11:25Z.
|
| Subjects: | |
| Online Access: | Get fulltext |